The success of infectious disease chemotherapy has been dimmed ever since the dawn of the antimicrobial drug era because of antibiotic resistance [18, 25] . Today, because of the emergence of resistant organisms [8, 22] , numerous diseases are becoming increasingly difficult to treat, including microorganisms responsible for severe infections in hospitalized patients, foodborne pathogens, and sexually transmitted pathogens, some of which are now resistant to most available antimicrobial drugs [20, 21, 26] . The clinical impact of resistance is immense, characterized by increased cost, morbidity, and mortality [3, 10] , hence the importance of developing new antimicrobial agents [2] .
Isocryptomerin is one of the biflavonoids isolated from Selaginella tamariscina, which belongs to Selaginellaceae, a traditional medicinal plant for therapeutic agents in the Orient. Previously, isocryptomerin was reported to suppress lymphocyte proliferation and showed cytotoxicity against human tumor cell lines [17, 23] . Although several biological properties of isocryptomerin were studied, its antimicrobial activity and potential as therapeutic agents in human microbial infections have not been studied.
In this study, we suggest isocryptomerin as a latent drug for bacterial diseases by investigating its novel antibacterial and synergistic activities with a conventional antibiotic.
Plant Material, Extraction, and Isolation Dried whole plants of Selaginella tamariscina Spring, which belongs to the Selaginellaceae family, were obtained from herbal drug stores in Gwangju. The plants were authenticated by the Department of Pharmacognosy, Chosun University. Voucher specimens (853-16) were deposited in the Herbarium of the College of Pharmacy, Chosun University. The whole plant of Selaginella tamariscina (0.6 kg) was extracted three times with MeOH at room temperature and evaporated to dryness under reduced pressure to obtain 50.54 g of residue. The methanol extract was suspended in water and then partitioned by dichloromethane, ethyl acetate, and n-butanol in turn. The EtOAc fraction (1. C NMR, and HSQC, of isocryptomerin were identical to those reported previously [17, 23, 15, 13] . The chemical structure of isocryptomerin is shown in Fig. 1 . . Methicillinresistant Staphylococcus aureus (MRSA) was clinically isolated from patients of the Kyungpook National University Hospital, Daegu, Korea. The MRSA isolate was screened for the presence of the mecA gene using PCR [6] . Bacterial cells (2×10 7 cells/ml) were inoculated into a Mueller-Hinton broth [12, 16] and 0.1 ml/well was dispensed onto 96-well microtiter plates. The bacteria numbers were calculated by measurement of turbidity with a spectrophotometer (DU530; Beckman, Fullerton, CA, U.S.A.) [19] . MICs (minimum inhibitory concentrations) were determined by a serial 2-fold dilution of test compounds, following the recommendations of the Clinical and Laboratory Standards Institute (CLSI) [7] . After 24 h of incubation at 37 o C, the minimal concentration of compound required to prevent the growth of a given test organism was determined and was defined as the MIC. The growth was assayed with a microtiter ELISA Reader (Molecular Devices Emax, CA, U.S.A.) by monitoring absorption at 620 nm [24] . In the present study, propionic acid and nisin were used as positive controls and purchased from the Sigma Chemical Co. (St. Louis, MO, U.S.A.). Propionic acid is an antibacterial agent that is widely used as a food preservative agent [5] . Nisin is used in processed cheese production to extend the shelf life by suppressing Gram-positive spoilage and pathogenic bacteria [1] . The result showed that isocryptomerin, in MIC values of 10-20 µg/ml, had remarkable antibacterial activity against Grampositive and Gram-negative bacteria including the clinical isolates of antibiotic-resistant bacteria like MRSA, responsible for difficult-to-treat infections in humans (Table 1 ). This result suggests that isocryptomerin can be applied as a therapeutic model for treating bacterial infectious diseases.
Antibacterial Activity of Isocryptomerin

Synergistic Activity of Isocryptomerin with Cefotaxime
Nowadays, abuse of conventional antibiotics to treat microbial infections has led to the emergence of antibiotics-resistant pathogens. Drug efflux transporters as MDR (multidrugresistant) pumps are capable of antibiotic resistance, because they selectively pump toxic molecules out to the extracellular condition by keeping toxic molecules to a minimum in an intracellular condition [11] . Above all, we examined sensitivities of antibiotics to MRSA. We used ampicillin, cefotaxime, chloramphenicol, kanamycin, and vancomycin as positive controls. These antibiotics were purchased from the Sigma Chemical Co. (St. Louis, MO, U.S.A.). Specifically, MRSA used in this study was not sensitive to several known antibiotics such as cefotaxime and kanamycin (Table 2) . One strategy employed to overcome these resistance mechanisms is the use of combination of antibiotics, such as β-lactams together with β-lactamase inhibitors [9] . Cefotaxime, one kind of commercial β-lactam antibiotics, is known to inhibit the synthesis of the bacterial cell wall by binding to the reactive Ser62 of the D-alanyl-D-alanine carboxypeptidase/ transpeptidase, which catalyzes the final step in the crosslinking of the bacterial cell wall peptidoglycan [14] .
The combination effect of isocryptomerin (2.3 µg) and cefotaxime (10 µg) was investigated against MRSA and the effects were evaluated by using the fractional inhibitory concentration index (FICI). FICI was calculated using the following formula: FICI=(MIC Drug A in combination/MIC Drug A alone)+(MIC Drug B in combination/MIC Drug B alone). Exponential phased cells of MRSA cultured in LB medium were seeded on 96-well microtiter plates at a density of 2×10 7 cells (100 µl per well). Isocryptomerin and cefotaxime were added to the well, and the cell suspension was incubated for 12 h at 37 o C. The activity was determined by measuring the absorbance at 620 nm using a microtiter ELISA Reader (Molecular Devices Emax, CA, U.S.A.). The FICI was Not determined. Fig. 1 . Chemical structure of isocryptomerin isolated from Selaginella tamariscina. calculated from both the FICI of isocryptomerin and cefotaxime. The FICI<0.5, 0.5≤FICI≤0.75, 0.76≤FICI≤1, 1<FICI≤4, and >4 were defined as synergy, partial synergy, additive effect, indifference, and antagonism, respectively [4] . The result exhibited that the combination of isocryptomerin with cefotaxime significantly improved the antibacterial activity compared with when tested alone. Based on the calculations, the combination of isocryptomerin and cefotaxime exhibited synergy, and showed the FICI value of 0.48 (Table 3) . This may be explained on the assumption that cefotaxime can inhibit the synthesis of the bacterial cell wall and, in succession, isocryptomerin exerts its antibacterial activity effectively against the weakened bacterial cells. This result also indicates that isocryptomerin may be used with established antibiotics for treating multidrug-resistant bacterial strains. In summary, this is the first study to investigate the antibacterial properties of isocryptomerin including its synergistic effects with existing antibiotics. Although the exact mechanism(s) that isocryptomerin exerts its antibacterial activity must be further investigated, the primary significance of this study is the suggestion of the potential of isocryptomerin as an adjuvant for antibacterial therapy for the treatment of infectious diseases caused by drug-resistant bacteria. According to the results, it can also be expected that isocryptomerin may be the basis for the development of new antibacterial agents having synergic activity with conventional β-lactam antibiotics. 
